Literature DB >> 30224849

Nimotuzumab in the Management of Recurrent Endometrial Carcinoma: A Case Report.

Shyamji Rawat1.   

Abstract

Entities:  

Year:  2017        PMID： 30224849      PMCID： PMC6133787          DOI： 10.1007/s13224-017-1056-6

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN： 0975-6434


× No keyword cloud information.
  4 in total

1.  Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients.

Authors:  B K M Reddy; V Lokesh; M S Vidyasagar; K Shenoy; K G Babu; A Shenoy; T Naveen; Bindhu Joseph; R Bonanthaya; P P Bapsy; Jayarama Shetty; Krishna Prasad; C R Tanvir Pasha
Journal:  Oral Oncol       Date:  2014-03-06       Impact factor: 5.337

2.  Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.

Authors:  Dirk Strumberg; Beate Schultheis; M E Scheulen; R A Hilger; J Krauss; N Marschner; F Lordick; F Bach; D Reuter; L Edler; K Mross
Journal:  Invest New Drugs       Date:  2010-12-21       Impact factor: 3.850

3.  Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.

Authors:  Mayra Ramos-Suzarte; Patricia Lorenzo-Luaces; Nery Gonzalez Lazo; Mayte Lima Perez; Jorge Luis Soriano; Carmen Elena Viada Gonzalez; Ivis Mendoza Hernadez; Yisel Ávila Albuerne; Beatriz Paredes Moreno; Eduardo Santiesteban Alvarez; Idael Pineda Callejo; José Alert; Juan Antonio Martell; Yanela Santiesteban Gonzalez; Yulainis Santiesteban Gonzalez; Horacio Astudillo de la Vega; Erika Betzabe Ruiz-Garcia; Tania Crombet Ramos
Journal:  Cancer Biol Ther       Date:  2012-06-01       Impact factor: 4.742

Review 4.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.